Nuke, using your logic we should all be very content with a small study because if it was a R-IT study patient number and it falls short of success then everyone would be pissed and it would be a black eye for all of us shareholders. ALZ disease isn’t going to disappear anytime soon so no need for a small company like AMRN to be connected to a large study (in terms of its drug) especially since it’s not even AMRN’s research in the first place.
News 
Market Data 
Discover 
